The Prognostic Significance of Immune-Related Metabolic Enzyme MTHFD2 in Head and Neck Squamous Cell Carcinoma
Open Access
- 11 September 2020
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 10 (9) , 689
Abstract
Metabolic dysregulation has emerged as a crucial determinant of the clinical responses to immunotherapy. The aim of this study was to determine the clinical significance of the candidate immune-related metabolic enzymes (IRMEs) methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2 (MTHFD2) in head and neck squamous cell carcinoma (HNSCC). The gene expression profile of HNSCC cohort and the corresponding clinical information were downloaded from The Cancer Genome Atlas (TCGA). The differentially expressed IRMEs were identified, and then, the prognosis-associated IRMEs were revealed by univariate cox regression analysis. The prognostic significance of MTHFD2 in HNSCC as well as the association between MTHFD2 and immune cell infiltration were further analyzed. A total of 121 significantly altered IRMEs were identified between HNSCC and normal tissues, and 21 IRMEs were found to be strongly associated with overall survival of HNSCC. Upregulation of MTHFD2 was positively correlated with adverse clinicopathological factors in TCGA HNSCC cohort, which was further validated with our own cohort using immunohistochemical analysis. Interestingly, bioinformatic analysis further revealed that increased MTHFD2 expression was negatively associated with NK cells activation, while positively correlated with mast cells activation. In conclusion, MTHFD2 overexpression is closely correlated with unfavorable prognosis of HNSCC, and it might play an important role in modulating the tumor immune microenvironment.Keywords
Funding Information
- National Natural Science Foundation of China (No. 81901006)
- Guangdong Medical Research Foundation (No. A2019299)
This publication has 26 references indexed in Scilit:
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2016
- Suppression of MTHFD2 in MCF-7 Breast Cancer Cells Increases Glycolysis, Dependency on Exogenous Glycine, and Sensitivity to Folate DepletionJournal of Proteome Research, 2016
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialThe Lancet Oncology, 2016
- Targeting MTHFD2 in acute myeloid leukemiaJournal of Experimental Medicine, 2016
- Dysregulated metabolism contributes to oncogenesisSeminars in Cancer Biology, 2015
- The folate-coupled enzyme MTHFD2 is a nuclear protein and promotes cell proliferationScientific Reports, 2015
- Mast cells as targets for immunotherapy of solid tumorsMolecular Immunology, 2015
- Epidemiologic Trends in Head and Neck Cancer and Aids in DiagnosisOral and Maxillofacial Surgery Clinics of North America, 2014
- NK Cells in Therapy of CancerCritical Reviews™ in Oncogenesis, 2014
- Mast cell: insight into remodeling a tumor microenvironmentCancer and Metastasis Reviews, 2011